Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Investor Presentation
Q1 FY27
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Discovery themes featuring this stockAmanta Healthcare Ltd (AMANTA) is currently trading at 206.65 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Amanta Healthcare Limited is a fully integrated sterile liquids pharmaceutical manufacturer and marketer focused on Large Volume Parenterals (LVPs) and Small Volume Parenterals (SVPs), using ABFS and ISBM technologies from a WHO‑GMP certified facility in Gujarat, with a 47-product portfolio, 320 distributors, and exports to 21 countries. The company is mid-inflection: FY25 revenues were INR275 crore and PAT turned positive to INR11 crore after prior losses, with a historical revenue CAGR of 11.8% (FY21–25); management targets a materially higher 20%+ CAGR over the next two years driven by capacity additions and product mix improvement. SteriPort®, Amanta’s differentiated two‑port ISBM polypropylene container, is the core revenue driver at ~40–44% of revenues and operates at high utilization (91%), giving the company pricing discipline, perceived sterility advantages over polyethylene containers, and a leadership position in the two‑port IV fluids niche. Near-term value drivers are capital‑led and operational: a large FY26 capex program (~INR130 crore) to add SteriPort and SVP capacity, plus a 10.8 MW captive solar plant (INR34.8 crore) expected to save ~INR9 crore annually, combined with a conservative FY27 revenue target near INR400 crore and margin expansion to mid‑20s percent EBITDA. Balance sheet momentum is visible: the company has reduced borrowings and debt‑to‑equity materially from FY23 levels, repaid higher‑coupon instruments, completed an IPO and private placement (INR20 crore), and is prioritizing accelerated deleveraging even while funding expansion.
Over the past 52 weeks, Amanta Healthcare Ltd has traded between a low of ₹93.10 and a high of ₹206.65. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Amanta Healthcare Ltd has a market capitalization of approximately 786.68. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Amanta Healthcare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 53.59 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 786.68 Cr, Amanta Healthcare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Amanta Healthcare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Amanta Healthcare Ltd is 53.59. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The IPO was stated as a ₹126 crore book-built issue and entirely a fresh issue, with total issue size shown as 1,00,00,000 shares aggregating up to ₹126 crore.
Bearish
5
Neutral
4
Bullish
5
Bearish
5
Neutral
4
Bullish
37
Bearish
0
Neutral
0
Bullish
32
Bearish
5
Neutral
4
Bullish
5
Bearish
5
Neutral
4
Bullish
5
Bearish
0
Neutral
0
Bullish
32
Bearish
0
Neutral
0
Bullish
32
Bearish
0
Neutral
0
Bullish
32
Amanta Healthcare Limited is a fully integrated sterile liquids pharmaceutical manufacturer and marketer focused on Large Volume Parenterals (LVPs) and Small Volume Parenterals (SVPs), using ABFS and ISBM technologies from a WHO‑GMP certified facility in Gujarat, with a 47-product portfolio, 320 distributors, and exports to 21 countries.
The company is mid-inflection: FY25 revenues were INR275 crore and PAT turned positive to INR11 crore after prior losses, with a historical revenue CAGR of 11.8% (FY21–25); management targets a materially higher 20%+ CAGR over the next two years driven by capacity additions and product mix improvement.
SteriPort®, Amanta’s differentiated two‑port ISBM polypropylene container, is the core revenue driver at ~40–44% of revenues and operates at high utilization (91%), giving the company pricing discipline, perceived sterility advantages over polyethylene containers, and a leadership position in the two‑port IV fluids niche.
Near-term value drivers are capital‑led and operational: a large FY26 capex program (~INR130 crore) to add SteriPort and SVP capacity, plus a 10.8 MW captive solar plant (INR34.8 crore) expected to save ~INR9 crore annually, combined with a conservative FY27 revenue target near INR400 crore and margin expansion to mid‑20s percent EBITDA.
Balance sheet momentum is visible: the company has reduced borrowings and debt‑to‑equity materially from FY23 levels, repaid higher‑coupon instruments, completed an IPO and private placement (INR20 crore), and is prioritizing accelerated deleveraging even while funding expansion.
Pharmaceuticals & Biotechnology
Pharmaceuticals
787 Cr
Low Risk
53.6
37.7
1.2
3.6
206.65
93.10
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
665.65 | 896 Cr | 58.04 | 5.50 | 0.00 | 10.90 | 14.23 | 7.43 | ||
242.80 | 865 Cr | 20.11 | 11.16 | 0.00 | 51.51 | 27.98 | 10.39 | ||
16.23 | 827 Cr | 29.47 | 3.59 | 0.00 | 12.38 | 16.89 | 9.04 | ||
67.41 | 789 Cr | 22.00 | 2.73 | 0.00 | 16.26 | 20.71 | 12.42 | ||
206.65 | 787 Cr | 53.59 | 3.57 | 0.00 | 7.46 | 9.58 | 2.63 | ||
302.40 | 730 Cr | 93.70 | 7.59 | 0.00 | 11.54 | 10.63 | 4.44 | ||
134.00 | 693 Cr | 187.30 | 2.36 | 0.00 | 1.97 | 5.07 | 0.69 | ||
| Median: 7 Co. | — | 206.65 | 789 Cr | 53.59 | 3.59 | 0.00 | 11.54 | 14.23 | 7.43 |
